Lannett Files ANDA For US Advair Rival
Firm Reveals It Is Also In Negotiations Over Additional Respiratory Opportunities
Lannett has become the latest company to file an ANDA for a generic rival to GSK’s Advair Diskus in the US. Meanwhile, the company has revealed that it is also exploring further respiratory opportunities.
You may also be interested in...
Lannett Looks To Transform Company With Five Pipeline Assets
With five “large, durable assets” in its pipeline, Lannett is confident that post approval these products have the potential to transform the company. This includes the generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) recently added to Lannett’s respiratory generics portfolio.
FDA Hands Lannett Goal Date On Generic Advair
Lannett continues to eye the potential launch of its partnered Advair generic next year, after the lucrative respiratory asset was accepted for filing by the FDA.
Lannett Bets On Respiratory And Insulins Pipeline As Sales Falter
Despite turnover dropping by over a fifth in its financial third quarter, Lannett says it is optimistic that respiratory generics and insulins will offer the firm “durable” opportunities in future. The company has also just reorganized its finances to extend its debt maturity by four years, pushing it back past some of its key launches.